Adding an antidepressant to cognitive behavioral therapy (CBT) appears to provide no extra gain over CBT by decreasing symptoms in teenagers with primary despair, new research indicates.
Investigators compared 12 weeks of remedy with a mixture of CBT and the selective serotonin reuptake inhibitor fluoxetine to CBT plus placebo in 153 young people (elderly 15 to 25 years) with mild-to-intense predominant depressive disease (MDD).
They determined no evidence that including fluoxetine vs. placebo to CBT, besides reduced depressive signs. However, the exploratory analysis did propose that adding drugs is probably beneficial for sufferers with comorbid tension signs and older young people.
“We found that mixed treatment with CBT and fluoxetine become no longer extra powerful than CBT and placebo, and in secondary analyses, we showed that this became specifically the case for members who were younger than 18,” lead creator Christopher Davey, MD, Ph.D., companion director of scientific services at Orygen Youth Health in Parkville, Australia, told Medscape Medical News.
“The consequences of the trial should make clinicians more cautious about dashing to start depressed young humans on medicine, in particular after they haven’t given [CBT] therapy a right risk,” said Davey, an important research fellow and head of mood problems research at Orygen.
Davey stated he was “motivated to undertake the look at due to ongoing uncertainty approximately the benefits of antidepressant medicinal drugs for young human beings.”
“Therein all fairness, accurate evidence that CBT is effective and must be offered as first-line treatment. However, there hasn’t been tons support for the not unusual exercise of starting antidepressant remedy simultaneously, specifically for younger people experiencing extraordinarily severe depression,” he said.
To look into the question, the researchers carried out the Youth Depression Alleviation–Combined Treatment (Yoda-C) trial that randomly assigned 153 individuals elderly 15 to 25 years (suggest [SD] 19.6 [2.7] years) to obtain either CBT plus placebo (n = seventy-seven) or CBT plus fluoxetine (n = seventy-six).
Eligibility requirements had been “broad and designed to reflect the real-global characteristics” of young people providing to scientific centers.
Participants could take benzodiazepines or benzodiazepine-like medicines during the trial but no longer antipsychotics or mood stabilizers.
Participants have been required to have been diagnosed with MDD based totally on the Structured Clinical Interview for DSM-IV Axis 1 Disorders (SCID-IV) and to have scored 20 or higher on the 1st viscount Montgomery of Alamein-Åsberg Depression Rating Scale (MADRS), “indicating melancholy of at the least moderate severity.”
Patients with beyond or contemporary psychosis, bipolar I or bipolar II disorder, pregnancy, or acute or unstable clinical diseases were excluded.
Participants started by taking one 20-mg pill of fluoxetine or one placebo tablet every day, with an opportunity of growing to fluoxetine 40 mg daily (or two placebo pills) within the event of inadequate medical response after the primary four weeks.
